Clinical Trial Update: SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases [Phase 2]

View source ↗

Summary

Phase 2 clinical trial SCRT-CAPEOX-Serplulimab for MSS/pMMR rectal cancer with oligometastases is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Serplulimab (serplulimab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Colorectal Carcinoma, Oligometastases | Phase 2 | Status: RECRUITING